Results 71 to 80 of about 43,229 (277)

Low Dose Pegylated Interferon Alpha as a First‐Line Treatment for Necrobiotic Xanthogranuloma

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiotic xanthogranuloma (NXG) is a rare, progressive granulomatous disorder frequently associated with monoclonal gammopathy, particularly monoclonal gammopathy of undetermined significance (MGUS). It typically presents with indurated to ulcerative yellowish plaques or nodules, often with ocular involvement.
Ishana Dixit, Charmaine Vanessa S. Chamberlin, Pablo Fernandez‐Peñas   +2 more
wiley   +1 more source

Advances in Elemene Nanodelivery Systems: From Material Design to Disease Treatment

Rare Metals, EarlyView.
ABSTRACT Elemene (ELE) is a bioactive sesquiterpenoid extracted from traditional Chinese herbs, demonstrating broad‐spectrum antitumor, anti‐inflammatory, and analgesic properties with significant therapeutic potential. However, its clinical utility is constrained by inherent physicochemical limitations, including volatility and hydrophobicity, which ...
Xiao Wang, Jiatong Lin, Yi Peng, Zehua Wu, Yingying Liu, Wei Duan, Qiaolin Wei, Jia‐Wei Shen, Jiang‐Xing Chen, Yong Guo   +9 more
wiley   +1 more source

Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C Doença celíaca após tratamento de hepatite C crônica com interferon peguilado e ribavirina

Arquivos de Gastroenterologia, 2004
AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.
Elson V. Martins Jr., Ana K. Gaburri
doaj   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report

Journal of Medical Case Reports, 2010
Introduction Hepatitis-associated aplastic anemia is a common syndrome in patients with bone marrow failure. However, hepatitis-associated aplastic anemia is an immune-mediated disease that does not appear to be caused by any of the known hepatitis ...
Ioannou Savvas, Hatzis Gregorios, Vlahadami Ioanna, Voulgarelis Michael   +3 more
doaj   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Acute pancreatitis associated with boceprevir: a case report

Brazilian Journal of Infectious Diseases, 2014
Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy,
Juliana Miguel Bilar, Roberto José Carvalho-Filho, Carolina Frade Magalhães Girardin Pimentel Mota, Patricia da Silva Fucuta, Maria Lucia Cardoso Gomes Ferraz   +4 more
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Virtual screening for NS5B inhibitors of Hepatitis C virus [PDF]

, 2012
Hepatitis C Virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at a risk of developing significant morbidity and mortality.
Achuthsankar S. Nair, Amjesh R, Sugunan V.S.   +2 more
core   +2 more sources

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

Transplant Infectious Disease, EarlyView.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni, Andrea Cona, Malgorzata Mikulska, Francesca Pecoraro, Carlotta Piazza, Elda De Vita, Giada Pietrosi, Matteo Bulati, Tiziana Lazzarotto, Mario Luppi   +9 more
wiley   +1 more source